



## ABOUT AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

## PIONEERING MEDICINES

We have a presence in approximately 100 countries worldwide and have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: oncology/haematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Our medicines typically address diseases for which the number of effective treatment options are limited, or they are medicines that provide a viable option to what is otherwise available.

## INNOVATIVE RESEARCH

Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines. Amgen's "biology first" approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. As advances in human genetics continue to shed new light on the molecular roots of disease, Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.

## WORLD-CLASS MANUFACTURING

The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.

### AMGEN QUICK FACTS

#### HEADQUARTERS

Thousand Oaks, California

#### STAFF

Nearly 20,000 worldwide

#### STOCK LISTING

NASDAQ: AMGN

#### CHAIRMAN AND CEO

Robert A. Bradway

#### 2017 FINANCIAL HIGHLIGHTS

Total revenue: USD 23 billion  
Product sales: USD 21.9 billion  
Non GAAP R&D expense:  
USD 3.8 billion

#### MISSION

To serve patients

#### VALUES

Be Science-Based

Compete Intensely and Win

Create Value for Patients, Staff and Stockholders

Be Ethical

Trust and Respect Each Other

Ensure Quality

Work in Teams

Collaborate, Communicate and Be Accountable

## ABOUT AMGEN AUSTRALIA

Established in 1991, Amgen Australia works to further the company's global efforts to transform the promise of science and biotechnology into therapies that have the power to restore health and save lives. Thousands of Australians use one of Amgen's 12 products and thousands more have been enrolled in clinical studies that have helped deliver the next generation of innovative treatments. Amgen Australia is proud to support these patients and to contribute to the development of new therapies in partnership with Australia's leading healthcare, academic, research, government and patient organisations.

## LOCAL RESEARCH AND DEVELOPMENT

Amgen maintains an extensive clinical trial program and invests significantly in research and development annually. Amgen's history of clinical trial activity in Australia dates back almost 30 years and our reputation for quality and safety continues to make us one of the most trusted destinations in the world for Amgen research. In 2017, this included 694 Australian patients, participating in 49 clinical trials, including 16 investigator-sponsored studies, at over 75 leading Australian hospitals. Importantly, Australia is a particularly sought-after location for Amgen's early development studies. In 2017, 22% of our work was in Phase I trials and first-in-human studies represented over half of this. Much of the current research focuses on advancements in haematology / oncology and cardiovascular disease and leverages Australia's high quality medical researchers and infrastructure to help bring new therapies from the laboratory to the marketplace.

## COMMUNITY SUPPORT

At the heart of Amgen Australia's operations is a genuine desire to make a positive impact, not only in the lab, but also in the wider community. This is realised through:

**The Amgen Foundation** - brings the excitement of discovery to the scientists of tomorrow through several programs, including Amgen Scholars, Amgen Biotech Experience, and Khan Academy. The Amgen Biotech Experience was launched into New South Wales high schools in 2017 in partnership with Sydney University. The Amgen Foundation also supports the Australian National Youth Science Forum (NYSF) to provide selected high school students with a hands-on opportunity to learn about the value, benefits, and possibilities of science, technology, engineering and maths (STEM)-related careers. For more information, visit [www.amgen.com.au/responsibility/commitment-to-science-education-in-australia/](http://www.amgen.com.au/responsibility/commitment-to-science-education-in-australia/)

**Local grants** - making a difference by enabling the work of others, particularly in the areas of clinical research and ongoing medical education.

**Patient organisations** - supporting Rare Cancers Australia, Osteoporosis Australia, Heart Foundation, Kidney Health Australia and others in their efforts to provide information, support and resources that improve prevention, diagnosis, treatment and survival.

**Volunteering** - providing every staff member with two days of paid charity leave so they can donate man-hours to important local community groups and projects.

**Environmental sustainability** - designing practices to measure and reduce environmental impact and build a culture of environmental awareness amongst employees.

## REWARDING CAREERS

Amgen Australia offers challenging and rewarding career opportunities for both experienced professionals and recent graduates. Amgen maintains a strong commitment to equal opportunity, gender equity and fosters an inclusive environment of diverse, committed and highly accomplished people. The company strives to promote a high-performing, team-based environment where employees embrace and leverage each other's talents and backgrounds, nourish innovative thinking, achieve their full potential, and contribute to our success. Visit our website to learn more about working at Amgen, or join our LiveHire Talent Community ([livehire.me](http://livehire.me)) to be considered for upcoming employment opportunities.

### AMGEN QUICK FACTS

#### AUSTRALIAN OFFICE LOCATIONS

##### Head Office (Sydney)

Level 7, 123 Epping Road  
North Ryde NSW 2113  
T: +61 2 9870 1333  
F: +61 2 9870 1344  
W: [www.amgen.com.au](http://www.amgen.com.au)

ABN 31 051 057 428

##### Melbourne Office

Mezzanine Level  
115 Cotham Road  
Kew, VIC 3101

T: +61 3 9854 9800  
F: +61 3 9818 5123

#### MEDICAL INFORMATION

T: 1800 803 638 (toll free)

#### MANAGING DIRECTOR

My Linh Kha

#### 2017 REVENUE

Approx AUD \$314.7 million

#### STAFF

200 full-time employees (as at May 2018)

#### PRODUCTS

Aranesp® (darbepoetin alfa)  
BLINCYTO® (blinatumomab)  
IMLYGIC™ (talimogene laherparepvec)  
Kyprolis® (carfilzomib)  
Neulasta® (pegfilgrastim)  
NEUPOGEN® (filgrastim)  
Nplate® (romiplostim)  
Prolia® (denosumab)  
Repatha™ (evolocumab)  
Sensipar® (cincalcet)  
Vectibix® (panitumumab)  
XGEVA® (denosumab)

For further information about our pipeline and therapies, visit [www.amgen.com.au](http://www.amgen.com.au)

#### AFFILIATIONS

Amgen is a proud member of:

- Medicines Australia
- AusBiotech
- American Chamber of Commerce in Australia (AmCham)